An Open Arm Pilot Study to Evaluate the Safety and Performance of the dCell Vascular Patch in Reconstructive Peripheral Vascular Surgery

Tissue Regenix Ltd4 sites in 2 countries21 target enrollmentAugust 2009

ConditionsPeripheral Arterial Vascular Occlusion

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Peripheral Arterial Vascular Occlusion
Sponsor: Tissue Regenix Ltd
Enrollment: 21
Locations: 4
Primary Endpoint: Maintenance of Arterial Patency
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study is designed to produce early safety and performance data in a small group of patients requiring repair of a peripheral vascular endarterectomy (incision into an artery feeding the limbs which requires a patch to repair the incision after removal of an atherosclerotic plaque that was stopping usual blood flow to the limbs).

Data is being collected to show the procedure is safe and allows for normal blood flow to be resumed.

Data will be used to facilitate CE Mark submission.

Registry

clinicaltrials.gov

Start Date

August 2009

End Date

November 2011

Last Updated

11 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Tissue Regenix Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients scheduled for a remote or open peripheral vascular endarterectomy
•Lack of suitable autologous material to function as closure patch for the arteriotomy
•Uncomplicated standard elective endarterectomy procedure (per-operative inclusion criteria)
•Use of dCell™ Vascular Patch as arteriotomy closure material (per-operative inclusion criteria)
•Patients between 18 and 80 years old, inclusive
•Haemoglobin \> 9 g/dL and platelet count \> 100,000/mm3 prior to Day 1
•Other haematological and biochemical parameters within a range acceptable for the administration of general anesthesia prior to Day 1
•Ability to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures
•Duly executed, written, informed consent obtained from patient

Exclusion Criteria

•Known serious allergy to contrast agent used for angiography
•Treatment with any investigational drug or device within 60 days prior to study entry (Day 1)
•If female and of child-bearing potential: evidence of a positive pregnancy test or a stated intention to become pregnant in the next 6-12 months
•Patients receiving a revision of an existing graft
•Patients demonstrating an active local or systemic infection (WBC \> 15,000/mm3)
•Any condition which in the judgment of the Investigator would preclude adequate evaluation of dCell™ Vascular Patch's safety and performance
•Patients on vitamin K antagonists